References
- Athale UH, Gibson PJ, Bradley NM, et al. Minimal residual disease and childhood leukemia: standard of care recommendations from the Pediatric Oncology Group of Ontario MRD Working Group. Pediatr Blood Cancer. 2016;63:973–982.
- Short NJ, Jabbour E. Minimal residual disease in acute lymphoblastic leukemia: how to recognize and treat it. Curr Oncol Rep. 2017;19:6.
- Yeung CC, Egan D, Radich JP. Molecular monitoring of chronic myeloid leukemia: present and future. Expert Rev Mol Diagn. 2016;16:1083–1091.
- Ivey A, Hills RK, Simpson MA. UK National Cancer Research Institute AML Working Group, et al. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016;374:422–433.
- Balsat M, Renneville A, Thomas X, et al. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association Group. JCO. 2017;35:185–193.
- Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
- Sung PJ, Luger SM. Minimal residual disease in acute myeloid leukemia. Curr Treat Options Oncol. 2017;18:1.
- Chen X, Othus M, Wood BL, et al. Flow cytometric demonstration of decrease in bone marrow leukemic blasts after ‘day 14’ without further therapy in acute myeloid leukemia. Leuk Lymphoma. 2017;58:2717–2719.
- Keeney M, Halley JG, Rhoads DD, et al. Marked variability in reported minimal residual disease lower level of detection of 4 hematolymphoid neoplasms: a survey of participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program. Arch Pathol Lab Med. 2015;139:1276–1280.